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In Australia, the greatest tonnage of antibiotics are prescribed in general practice.1,2 Their over-prescription may 
be contributing to antibiotic resistance.3 
This is recognised as a serious threat, putting 
recovery from serious infection in doubt, 
and beginning to risk many therapeutic 
and diagnostic interventions in tertiary care 
requiring secure antibiotic cover – something 
now labelled a global threat.4,5 
Several guidelines exist in Australia 
to guide primary care. The Australian 
(electronic) Therapeutic Guidelines (eTG)6 
are widely used; these give evidence-based 
recommendations on the basis of a diagnosis 
with a rank order provided for recommended 
antibiotics, along with dose, frequency and 
– importantly – duration. There are other 
equally evidence-based guides such as 
the Australian Medicines Handbook,7 these 
recommend antibiotics to use for different 
indications (based on the likely infecting 
organism) and their doses, frequencies, and 
sometimes duration. Antibiotics are almost 
universally packaged by manufacturers in 
packs that heavily influence duration. This 
had us speculate on the extent packing size 
matches the guideline recommendations for 
duration; any mismatch might contribute to 
unused antibiotics in the community and, if 
taken by patients on some other occasion, 
may contribute to unprescribed use and, 
thereby, resistance. 
Methods
A wide range of antibiotics is used in 
primary care for a large array of different 
indications. These infections make up 
15% of the total number of problems 
managed in general practice; most are 
respiratory, urinary and skin.2 We elected 
to limit the study to a manageable size 
by identifying the three most common 
indications for the four most frequently 
prescribed antibiotics. The numbers of 
prescriptions for each oral antibiotic derived 
from the Australian Statistics on Medicines 
(ASM) 2010 (representing prescriptions 
dispensed through the Pharmaceutical 
Benefits Scheme [PBS], the Repatriation 
Pharmaceutical Benefits Scheme [RPBS], 
and private prescriptions estimates through 
community pharmacy surveys)8 were totalled 
and ranked. Because the ASM does not 
collect indications for the prescriptions, we 
identified the most common indications for 
each antibiotic derived from the Australia 
2012–2013 BEACH database.2 Finally, we 
extracted the data for these antibiotics and 
indications, recommended by the eTG).6 This 
information source was chosen from those 
recommended by the Australian Health 
Practitioner Regulation Agency (AHPRA)9,10 
and routinely used by health professionals, as 
it makes evidence-based recommendations 
on the basis of illness diagnosis as specified in 
the introduction (Table 1).
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Abstract
Objectives: To determine the potential for a source of surplus antibiotics in the community 
to come from the mismatch between the recommended duration of antibiotic treatment for 
common indications in primary care and that dictated by default pharmaceutical industry 
packaging.
Methods: Analysis of existing published information of: 1) the most common antibiotics 
prescribed in primary care in Australia; 2) their most common indications; 3) the guideline 
recommendations for their duration; and 4) the duration dictated by antibiotic packaging. 
Results: Of 32 common antibiotic prescribing scenarios, 10 had doses left over in surplus 
and 18 had a shortfall, leaving only four in which the packaging size matched the duration 
recommended by electronic Therapeutic Guidelines. Where there was a shortfall, this was only 
exactly accommodated by a repeat prescription in two cases. 
Conclusions: Mismatch contributes to a shortfall or excess of doses compared to 
recommended antibiotic treatment protocols and probably exaggerates redundant doses in 
the community from prescribed antibiotics dispensed and not consumed. 
Implications: Prescribers need to be aware that the mismatch between antibiotic pack sizes 
and guideline recommendations for their duration is contributing to antibiotic resistance in the 
community.
Key words: infectious diseases, prescribing, pharmacology, antibiotic resistance, drug 
utilisation
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There are differences in definition of 
diagnostic entities for these data sources. 
BEACH uses the International Classification 
of Primary Care, 2nd Edition (ICPC2).11 The 
eTG, however, uses different diagnostic 
entities and we had to map these to each 
another (Table 2). This is not exact; for 
example, the second most common acute 
respiratory infection recorded in the BEACH 
dataset is ‘Acute Bronchitis/Bronchiolitis’, 
which probably captures several distinct 
entities, including acute exacerbations of 
chronic obstructive pulmonary disease, 
acute cough associated with undifferentiated 
respiratory infection, Mycoplasma infection 
and others. Bronchiolitis is largely confined 
to the first year of life. Meanwhile, eTG 
includes influenza, pharyngitis and/or 
tonsillitis, acute epiglottitis (supraglottitis), 
otitis externa, otitis media, pertussis, acute 
bronchiolitis, rhinosinusitis, acute bronchitis, 
acute exacerbations of chronic obstructive 
pulmonary disease and croup among “other 
respiratory tract infections”, (Table 2). 
Number of doses of antibiotic required 
(milligram strength, frequency and duration) 
was based on the eTG recommendations 
for each antibiotic and compared with 
the number of doses provided in a single 
standard pharmaceutically packaged 
antibiotic (using three typical patients: an 
adult; an eight-year-old child [25 kg], and a 
one-year-old child [10kg]). We did not use 
the World Health Organization’s “defined 
daily dose” (DDD) because this is defined on 
assumed average maintenance doses rather 
than reflecting any guideline.12
We assumed that antibiotics chosen to treat 
frequent presentations of acute bronchitis 
would be directed at common causes of 
Table 1:   Dosing/Duration Information available from AHPRA recommended health practitioner medicines information sources
Source Approach Example Amoxycillin (oral treatment dose)
Australian Medicines 
Handbook (AMH)7
Structured as drug monographs within therapeutic classes providing:
•	A generic dose range and frequency for the specified antibiotic but not usually a 
recommended duration
•	Dose and frequency and duration are listed only for a limited number of indications 
(e.g.  for amoxicillin only two less common indications) 
Adult: Oral, 250–500 mg every 8 hours or 1 g tablet twice a day. Doses of 1 g every 
8 hours may be used in severe infections, e.g. pneumonia.
•	 Gonococcal infection: For confirmed non-beta-lactamase-producing N. 
gonorrhoeae. Oral, 3 g single dose with probenecid
•	 Eradication of H. pylori: With clarithromycin, oral 1 g amoxycillin twice daily for 
7 days OR With metronidazole, oral 500 mg amoxycillin 3 times daily for 14 days.
Child: Oral, 15–25 mg/kg (max 500 mg) every 8 hours. For severe infections up to 
30 mg/kg (max 1 g) every 8 hours can be used.
Australian Pharmaceutical 
Formulary and Handbook 
(APF)13
Drug (antibiotic) monographs listed alphabetically provide:
•	Only a ‘common dose range’ that includes a generic dose and frequency but for the 
specified antibiotic  no recommended duration
•	Individual dose and frequency recommendations are not differentiated for common 
indications
Common dosage range
Adult dose: OraL, 250-500 mg 8-hourly or 1 g twice daily
Paediatric dose: Oral, 7.5-25 mg/kg 8-hourly
Product Information
(accessed as package 
insert or via tertiary 
information sources such 
as MIMS, AusDi) 
Antibiotic monograph usually provides:
•	Microbiology sensitivity/resistance tables but these are not clearly linked to indication
•	A list of indications for the specified antibiotic by broad organ system e.g. upper 
respiratory tract infections or skin and soft tissue infections rather than for specific 
indications e.g. bronchitis, UTI
•	Tailored dose and frequencies for a subset of selected indications, however durations 
are not routinely specified.
Amoxil brand: Dosage and administration: Normal Renal Function: Upper respiratory 
tract infections; genito-urinary tract infections; skin and soft tissue infections.
Adults – 250 mg every eight hours.
Children (under 20 kg) – 20 mg/kg/day in equally divided doses every eight hours.
In severe infections or those caused by less susceptible organisms, 500 mg every 
eight hours for adults and 40mg/kg/day in equally divided doses every eight hours 
for children may be needed.
Lower respiratory tract infections.
Adults – 500 mg every eight hours.
Children (under 20 kg) – 40 mg/kg/day in equally divided doses every eight hours.
Urethritis, gonococcal. Adults – 3 g as single dose.
Acute, uncomplicated lower urinary tract infections in non-pregnant adult female. 
Adults – 3 g as single dose.
eTherapeutic Guidelines 
(eTG)6
Information primarily classified by indication (not as individual drug e.g. antibiotic 
monographs)
•	Searching by name of drug leads to an index list of indicated uses (diagnoses), 
selection of an indication leads to information on ranked choice of drug, dose, 
frequency and duration
•	Information represents Australian guidelines for recommended therapy for each 
specified indication including individual antibiotic protocols (drug, dose, frequency 
and duration).
•	Information is based on evidence in literature  and consensus expert 
recommendations on treatments of specific infections 
Alphabetical Index for Amoxycillin by Therapeutic use retrieved > 25 individual 
indications
For example:
For Rhinosinusitis: If antibiotics are indicated, use: amoxycillin 500 mg (child: 15 mg/
kg up to 500 mg) orally, 8-hourly for 5-7 days
For Acute Otitis Media  – children with systemic features, use amoxycillin 15 mg/kg 
up to 500 mg orally, 8-hourly for 5 days
Table 2: Mapping different diagnostic categories from BEACH to eTG, and their rank order.
ICPC Respiratory infection terms BEACH ranking of frequency 
of Respiratory Infection in GP
eTG Respiratory infection terms 
Upper respiratory infection acute 1 Upper respiratory tract infection
Acute bronchitis/bronchiolitis 2 Acute bronchitis (infections including acute bronchitis)
Acute bronchiolitis
Sinusitis acute/chronic 3 Rhinosinusitis/acute bacterial rhinosinusitis
Acute otitis media 4 Otitis media
Tonsillitis acute 5 Acute Pharyngitis and/or tonsillitis
Strep throat 5 Acute Pharyngitis and/or tonsillitis
ICPC: International Classification for Primary Care9
BEACH: Bettering the Evaluation And Care of Health2
eTG: (electronic) Therapeutic Guidelines6
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Table 3: Match between guidelines for the duration of commonly prescribed antibiotics and their pack sizes, antibiotic and indication by order of frequncy of use in Australia. 
Antibiotic
 Infection indication
doses/ 
day
Duration 
suggested 
by guideline 
(Days)b
Duration dictated by pack size (Days)a
Adult
Child 8 yrs, 
25Kg
Child 1 yr, 
10 Kg
    -20            -15              -10               -5               -1 1                5                10                15                20 +1              +5               +10     +12
Shortfall of doses    Pack/bottle size (no. of doses)c      Extra doses (left over)c
Amoxicillin 500mg 
x 20
50mg/ml x 
100ml
25mg/ml x 
100ml
 Bronchitisd,e
 Sinusitisf
 Otitis mediaf
3
3
3
3
3
3
3
3
3
5
5
3
5
5
5
5
5
5
6.7
6.7
6.7
2.7
4.4
4.4
3.3
5.5
5.5
 


















Cephalexin 500mg 
x 20
50mg/ml x 
100ml
25mg/ml x 
100ml
 Urinary tract infectiong
 Skin infectionh,i
 Bronchitis
2
2
4
4
2
2
2
5 (female)
14 (male)
5
5
5
5
5
N/I
10
10
5
N/I
4
4
N/I
5
5
N/I











Amoxycillin+Clavulanate (A+C) See notes 
j,k,l,m
80+11.4mg/
ml x60ml
80+11.4mg/
ml x60ml
 Sinusitisj
 Urinary tract infectionl
 Otitis mediaj
3
3
3
2
2
2
2
3
3
3
7
7
7
5 (female)
14 (male)
5
5
5
5
5
3.3(k)
5(m)
5(m)
3.3(k)
2.8
4.3
2.8
7.1
10.7
7.1


















Roxithromycin 300mg x 5 50mg x 10 50mg x 10
 Bronchitis
 Streptococcal throatn,o
 Skin infectionn,o,q
1
1
2
2
1
2
2
N/I
10
10
10
10
10
10q
N/I
5
5
N/I
2.5
2.5
N/I
5p
5p












a: The most appropriate form and strength of antibiotic was chosen for age according to recommendations in Therapeutic Guidelines for treatment of specified infection; b: The shortest course of the recommended treatment was chosen, when 
open to choice; c: Doses rounded to nearest whole dose; d: The most common subgroup taken as “non-severe suspected bacterial pneumonia, or exacerbations of prior COPD; e: Amoxicillin  per dose: ‘bronchitis’ (d) 500mg (child amoxycillin 25 
mg/kg orally up to 1g); f: Amoxicillin per dose: sinusitis & otitis media 500mg (child 15mg/kg to max of 500mg); g: Cephalexin per dose: UTI 500mg (child 12.5mg/kg up to 500mg); h: Boils and carbuncles/ Staphylococcus; i: Cephalexin per dose 
(h): Boils & carbuncles 1 g (child: 25 mg/kg up to 1 g) orally, 12-hourly for 5 days.; j: Amoxicillin + clavulinate per dose: amoxycillin resistance suspected/proven: 875+25mg (child: 22.5+3.2 mg/kg up to 875+25 mg) for 7 days; k: Amoxicillin 
+ clavulinate 875+125mg; l: Amoxicillin + clavulinate per dose: UTI 500mg+125 (child  22.5+3.2 mg/kg up to 875mg); m:)Amoxicillin + clavulinate 500+125mg; n: If there is penicillin allergy; o: Roxithromycin per dose: 300mg (child 4mg/
kg up to 150mg); p: As dose for one year old is 0.8 tablet, 0.2 is wasted; q: Staphylococcal or streptococcal infection; N/I = Not indicated
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community acquired pneumonia such as 
Streptococcus pneumoniae and Haemophilus 
influenzae; urinary tract infection in non-
pregnant women and men was directed at 
Escherichia coli; and skin infections (boils/ 
carbuncles, and “other skin infections”) 
directed at Staphylococcus and Streptococcus 
species. 
Results
We consistently found a mismatch between 
the number of doses and the duration 
mandated by standard packaging sizes and 
recommended by guidelines for the most 
commonly prescribed antibiotics and their 
indications in primary care (see Table 3).The 
four most commonly prescribed antibiotics 
are specified in the Table. For each one, the 
top three ranked indications are listed in 
an individual column. There are three rows 
for each indication, showing the doses and 
duration recommended by the guideline 
versus the duration dictated by the pack 
size, calculated for an adult, 25 kg child and 
10 kg child. The number of doses available 
in a single proprietary pack of the specified 
antibiotic at the recommended ranged from 
five to 20 (represented by filled circles) with 
any shortfall or extra doses left in the pack 
represented by unfilled circles. Out of 32 most 
common antibiotic-prescribing scenarios, 
10 had doses left over in surplus and 18 had 
a shortfall, leaving only four in which the 
packaging size resulted in the exact duration 
recommended by eTG guidelines. Where 
there was a shortfall, this was only exactly 
accommodated by a repeat prescription in 
two cases (Table 3). 
Discussion 
This mismatch in duration between 
guidelines and that dictated by packaging 
may mean that a considerable quantity of 
antibiotics are dispensed and not consumed 
for the prescribed acute illness, contributing 
to redundant antibiotic doses in the 
community. Since the mismatch is the rule 
rather than the exception, we can speculate 
that this is a large quantity. 
Weaknesses in this study include the use 
of just one set of guidelines. However, this 
commonly used resource proved the most 
robust across the AHPRA recommended 
information sources. The difficulty we 
encountered in mapping the eTG diagnostic 
categories, and those set by the BEACH 
data-collection classification, mean that 
some diagnoses may be inaccurate – with 
implications for both the most common 
rubric as well as the best guidelines to fit the 
diagnosis. Nevertheless, we have seen no 
other studies that have considered this issue. 
There are, of course, other contributions 
to unused antibiotics in the community, 
including repeat prescriptions (sometimes 
inadvertently delivered by default settings 
in general practice prescribing software) 
and the failure by patients to complete the 
prescribed course. 
Nonetheless, our finding represents a 
problem that is probably more extensive 
than most prescribers realise. It Is unlikely 
that all primary care clinicians follow optimal 
guidelines in their antibiotic prescribing – this 
is one of the causes of antibiotic resistance.3 
Yet evidence-based guidelines are seen 
as an important means of changing over-
prescribing. Even if general practitioners 
attempt to follow guidelines, difficulties in 
matching diagnoses and trying to match pack 
size with recommendations is an important 
obstacle to their doing so effectively. 
Solutions are not obvious. One would 
be changes to legislation so that the 
Therapeutic Goods Administration (TGA) 
requires manufacturers to package 
antibiotics in accordance with guideline 
recommendations. However, this would be 
difficult as the same antibiotic is prescribed 
for several indications and for different 
durations; and resistance is likely from the 
pharmaceutical industry. Another solution 
would be to educate general practitioners 
in specifying the guideline recommended 
duration for antibiotics when prescribing 
them, thereby overriding the default pack 
quantity in their prescribing software and 
instead incorporating an algorithm derived 
from guidelines to calculate the associated 
required quantity. However, even if general 
practitioners could be persuaded to change 
their usual behaviour, pharmacists would 
need corresponding dispensing software to 
calculate and pass on the costs to the PBS, 
RPBS or private health funds for the extra time 
and stock loss, and the implementation of 
safety strategies to prevent the reuse of part-
packs with varying expiry dates associated 
with removing doses from their packages. 
Nonetheless, some solution needs to be 
trialled to close off what may be another 
threat to antibiotic resistance in the 
community. 
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